INDV

Business Context and Reporting Period

Company: Indivior PLC (trading as Indivior Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A global pharmaceutical company focused on treating opioid use disorder (OUD). Key products include SUBLOCADE (long-acting injectable), SUBOXONE (sublingual films/tablets), and OPVEE (nasal spray). The company operates as a single segment with the majority of revenue derived from the U.S. market.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company returned to profitability in Q2 2025 ($18M net income) compared to a significant loss in Q2 2024 ($97M net loss). This improvement is primarily driven by the absence of a $160M litigation settlement expense recorded in Q2 2024.
• Revenue Growth: Total net revenue increased 1% in Q2 2025 and decreased 3% YTD 2025. U.S. SUBLOCADE revenue grew 9% in Q2 and 4% YTD, offsetting declines in legacy sublingual products (down 18% in Q2) and PERSERIS (down 37% in Q2).
• Margin Expansion: Gross margin improved to 83% in Q2 2025 from 74% in Q2 2024. The prior year was negatively impacted by $41M in costs related to the discontinuation of PERSERIS marketing.
• Tax Impact: The effective tax rate for Q2 2025 was 71% (vs. 19% benefit in Q2 2024) due to a $33M tax reserve for a U.K. HMRC settlement and a U.K. global minimum top-up tax.
• Cash Position: Cash and cash equivalents increased to $510M from $319M at year-end 2024, driven by strong operating cash flow ($233M YTD) and timing of government rebate payments.

Guidance, Outlook, and Risks

• Outlook: Management expects gross margins to remain in the low-to-mid 80% range for the remainder of 2025. R&D expenses are expected to track below 2024 levels as the pipeline refocuses on Phase 2 OUD assets. Capital expenditures are projected at $50M–$70M for full-year 2025, primarily for the Raleigh Manufacturing Facility.
• Liquidity: The company maintains negative working capital ($106M deficit) due to the timing of rebate payments versus receivables. Management believes existing cash, investments, and operating cash flow are sufficient to meet obligations for at least 12 months.
• Legal Contingencies:
  • Opioid Litigation: A $79M provision has been recorded for a settlement covering certain opioid litigation (MDL). Private plaintiff cases remain unresolved.
  • Dental Litigation: Over 1,800 cases consolidated in MDL alleging dental injury from SUBOXONE Film. No estimate of loss can be made at this time.
  • Shareholder Claims: U.K. multiparty actions and U.S. class actions regarding securities laws remain pending, though some motions to dismiss have been granted.
• Regulatory Risks: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 introduces tax law amendments and potential changes to Medicaid eligibility and funding that could impact revenue and margins. Tariff uncertainties also pose a risk to raw material costs and IP licensing.
• Corporate Changes: The company completed its delisting from the London Stock Exchange in July 2025 and now trades exclusively on Nasdaq. It no longer qualifies as a "foreign private issuer" as of June 30, 2025.

Investor Verification Checklist

• Rebate Timing: Verify the sustainability of the $120M cash benefit from delayed government rebate invoice processing, as management expects rebate payments to increase in Q3 2025.
• Tax Reserve: Confirm the finality of the $33M U.K. HMRC tax reserve and its impact on future effective tax rates.
• Litigation Exposure: Monitor the opt-in process for the opioid MDL settlement (expected completion by Nov 2025) and the status of private plaintiff and dental injury lawsuits which are not covered by current accruals.
• Product Mix: Track the erosion of legacy SUBOXONE Film market share versus the growth trajectory of SUBLOCADE to ensure revenue stability.
• Regulatory Impact: Assess the specific implications of the OBBBA on Medicaid formularies and patient eligibility for OUD treatments.